In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue SUPPL. C, 1999, Pages 9-14

  Fremaux A ^a   Sissia, G ^a   Geslin, P ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; BACTERIOSTASIS; CONFERENCE PAPER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SCIENTIFIC LITERATURE; STREPTOCOCCUS PNEUMONIAE;

EID: 0344867851     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.suppl_3.9     Document Type: Conference Paper

References (29)

1. Baquero, F. (1996). Epidemiology and management of penicillin-resistant pneumococci. Current Opinion in Infectious Diseases 9, 372-9.
2. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1992). Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin and ciprofloxacin. Antimicrobial Agents and Chemotherapy 36, 856-9.
3. Cooper, B. & Lawlor, M. (1989). Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. American Journal of Medicine 87, 475.
4. Frieden, T. R. & Mangi, R. J. (1990). Inappropriate use of oral ciprofloxacin. Journal of the American Medical Association 264, 1438-40.
5. Gordon, J. J. & Kauffman, C. A. (1990). Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. American Journal of Medicine 89, 383-4.
6. Davis, R. & Bryson, H. M. (1994). Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47, 677-700.
7. Yamane, N., Jones, R. N., Frei, R., Hoban, D. J., Pignatari, A. C. & Marco, F. (1994). Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. Journal of Chemotherapy 6, 83-91.
8. Barry, A. L., Fuchs, P. C., Allen, S. D., Brown, S. D., Jorgensen, J. H. & Tenover, F. C. (1996). In-vitro susceptibility of Streptococcus pneumoniae to the D-and L-isomers of ofloxacin: interpretive criteria and quality control limits. Journal of Antimicrobial Chemotherapy 37, 365-9.
9. Eliopoulos, G. M., Wennersten, C. B. & Moellering, R. C. (1996). Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagnostic Microbiology and Infectious Disease 25, 35-41.
10. Rastogi, N., Goh, K. S., Bryskier, A. & Devallois, A. (1996). Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin and clofazimine. Antimicrobial Agents and Chemotherapy 40, 2483-7.
11. File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 41, 1965-72.
12. Kitzis, M. D., Goldstein, F. W. & Acar, J. F. (1995). Selection of one step resistant mutants of S. pneumoniae by levofloxacin compared with other fluoroquinolones. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract C126. American Society for Microbiology, Washington, DC.
13. Drugeon, H. B., Juvin, M. E. & Bryskier, A. (1997). Relative potential for selection of fluoroquinolone-resistant S. pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. Journal of Antimicrobial Chemotherapy 43, Suppl. C, 55-9.
14. Antibiogram Committee of the French Society of Microbiology Communiqué (1997). Pathologie Biologie 45, I-XII.
15. Johnson, A. P., Speller, D. C., Warner, M. & Domingue, G. (1996). In-vitro activity of levofloxacin (L-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales. Journal of Antimicrobial Chemotherapy 38, 907-8.
16. Klugman, K. P., Capper, T. & Bryskier, A. (1996). In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrobial Agents and Chemotherapy 40, 2802-4.
17. George, J. & Morrissey, I. (1997). The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 39, 719-23.
18. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1995). Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs 49, Suppl. 2, 235-7.
19. Markus, A., Isert, D., Kiesel, N. & Seibert, G. (1995). Killing activity of levofloxacin (LVFX) and ciprofloxacin (CIP) against Streptococcus pneumoniae in vitro and in vivo. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract E30. American Society for Microbiology, Washington, DC.
20. Visalli, M. A., Jacobs, M. R. & Appelbaum, P. C. (1997). Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagnostic Microbiology and Infectious Disease 28, 131-7.
21. Hoogkamp-Korstanje, J. A. A. (1997). In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. Journal of Antimicrobial Chemotherapy 40, 427-31.
22. Biedenbach, D. J. & Jones, R. N. (1996). The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagnostic Microbiology and Infectious Disease 25, 47-51.
23. Pfaller, M. A. & Jones, R. N. (1997). Comparative antistreptococcal activity of two newer fluoroquinolones, levofloxacin and sparfloxacin. Diagnostic Microbiology and Infectious Disease 29, 199-201.
24. Fu, K. P., Lafredo, S. C., Foleno, B., Isaacson, D. M., Barrett, J. F., Tobia, A. J. et al. (1992). In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrobial Agents and Chemotherapy 36, 860-6.
25. Gehanno, P. & The Members of the French Sinusitis Study Group. (1998). Oral levofloxacin, 500 mg once daily, in the treatment of acute maxillary sinusitis in adults. In Program and Abstracts of the Second European Congress of Chemotherapy, Hamburg, Germany, 1998. Abstract T106, p. 62. European Society for Biomodulation and Chemotherapy.
26. Shah, P. M. & Members of the International Study Group. (1997). Levofloxacin (LVFX) vs. cefuroxime axetil (CA) in the treatment of acute exacerbations of chronic bronchitis (AECB). In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract LM 38, p. 371. American Society for Microbiology, Washington, DC.
27. DeAbate, C. A., Russell, M., McElvaine, P., Faris, H., Upchurch, J., Fowler, C. L. et al. (1997). Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respiratory Care 42, 206-13.
28. Norrby, S. R., Petermann, W., Willcox, P. A., Vetter, N. & Salewski, E. (1998). A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scandinavian Journal of Infectious Diseases 30, 397-404.
29. Carbon, C. & Members of the International Study Group. (1997). Comparative study of levofloxacin (LVFX) and co-amoxiclav (Co-AC) in the treatment of community-acquired pneumonia (CAP) in adults. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada 1997. Abstract LM 70, p. 377. American Society for Microbiology, Washington, DC.